Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716650 | 0.77 | TP53 (0.42) | KDM4EEPHX2KMT2AALDH1A1MEN1 | |
| SCHEMBL3317207 | 0.76 | CASR (0.42) | KMT2AALDH1A1MEN1L3MBTL1GAA | |
| SCHEMBL12813567 | 0.70 | ACACB (0.53) | KDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL3317179 | 0.69 | NPC1 (0.61) | KMT2AALDH1A1MEN1L3MBTL1GAA | |
| SCHEMBL4711078 | 0.69 | L3MBTL1 (0.42) | KDM4EEPHX2KMT2AALDH1A1MEN1 | |
| SCHEMBL26076505 | 0.68 | PPARG (0.46) | KMT2AALDH1A1DPP4FAPDPP8 | |
| SCHEMBL19295493 | 0.68 | KDM4E (0.53) | KDM4EKMT2AALDH1A1L3MBTL1GAA | |
| SCHEMBL19295494 | 0.68 | KDM4E (0.53) | KDM4EKMT2AALDH1A1L3MBTL1GAA | |
| SCHEMBL7629121 | 0.68 | KDM4E (0.53) | KDM4EKMT2AALDH1A1L3MBTL1GAA | |
| SCHEMBL11581985 | 0.68 | HSD17B10 (0.53) | KDM4EEPHX2KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | KDM4E 4603/4885EPHX2 1305/4885KMT2A 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.